Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
LeRoy, New York, United States, 14482
- Place Eye Care
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subject is a habitual wearer of a silicone hydrogel or group IV contact lens
- VA correctable to 0.3 LogMar or better (driving vision)
- Clear central cornea
- Subject uses a lens care system on a regular basis
Exclusion Criteria:
- Systemic disease affecting ocular health
- Using systemic or topical medications
- wear monovision, multifocal or toric contact lenses
- Any grade 2 or greater slit lamp findings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Multipurpose Solution - Rub Care
Bausch & Lomb Multipurpose Solution for use with contact lens care
|
Daily care for contact lenses - rub care regimen
|
|
Experimental: Multipurpose Solution - No Rub Care
Bausch & Lomb Multipurpose Solution for use with contact lens care
|
Daily care for contact lenses - no rub care regimen
|
|
Active Comparator: Ciba Vision Aquify Multipurpose Solution
Ciba Vision Aquify Multipurpose Solution for use with contact lens care
|
daily care for contact lenses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Slit-lamp Findings > Grade 2
Time Frame: Over 4 visits for 3 month period
|
eyes with any slit lamp findings greater than Grade 2 at any visit.
Slit lamp findings for each eye will be graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding).
Epithelial edema, epithelial microcysts, corneal staining, limbal injection, bulbar injection, superior tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be assessed.
|
Over 4 visits for 3 month period
|
|
Subjective Responses to Comfort Related Symptoms/Complaints
Time Frame: Over 4 visits for the 3 month period
|
Subject symptoms/complaints will be assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.
|
Over 4 visits for the 3 month period
|
|
Contact Lens Deposits
Time Frame: At each visit for 3 months
|
Lens deposits assessed at each follow-up visit.
Degree of deposits assessed as none, light, medium, or heavy.
|
At each visit for 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mohinder Merchea, OD, PhD, Bausch & Lomb Incorporated
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 554
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.